The future of weight loss is fast approaching.
Newer treatments in the works are poised to compete with and possibly surpass both of these drugs.
Companies presented preliminary data on over two dozen GLP-1 related drugs, all in various stages of development.
Novo Nordisk’s semaglutide is the active ingredient in popular drugs Ozempic and Wegovy.Photo: Jaap Arriens/NurPhoto (Getty Images)
Its very exciting to see so much right now.
Some experts areskepticalthat lean body mass loss is a major concern with these drugs.
News from the future, delivered to your present.